BDKRB2 anticorps (C-Term, Intracellular)

N° du produit ABIN7886089

Cet anticorps anti-BDKRB2 Polyclonal Lapin (ABIN7886089) détecte spécifiquement BDKRB2 dans WB, IHC, IF et IC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour BDKRB2 anticorps (C-Term, Intracellular) (ABIN7886089)

Antigène: BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BDKRB2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunochromatography (IC)

Détail du produit anti-BDKRB2 anticorps

Épitope: AA 336-349, C-Term, Intracellular

Fonction: A Rabbit Polyclonal Antibody to B2 Bradykinin Receptor

Réactivité croisée: Humain, Souris, Rat

Homologie: mouse - 11,Rat - 12,13 amino acid residues identical

Attributs du produit: Anti-B2 Bradykinin Receptor (BDKRB2) Antibody (ABIN7042968, ABIN7043942 and ABIN7043943) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot, immunohistochemistry, and immunocytochemistry applications. It has been designed to recognize B2R from human, rat, and mouse samples.

Purification: Affinity purified on immobilized antigen.

Immunogène: GKRFRKKSWEVYQG(C), corresponding to amino acid residues 336-349 of human B2R

Isotype: IgG

Information d'application

Indications d'application:

WB: 1:1000

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: The optimal concentration should be determined by the user

IP: The optimal concentration should be determined by the user

Commentaires:

Cited Application: IHC

Negative Control: (ABIN7234872)

Blocking Peptide: (ABIN7234872)

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Détails sur BDKRB2

Antigène: BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

Autre désignation: BDKRB2

Sujet:

Synonyms: B2R, BKR2, B2BKR, BKRB2, Kinin B2, BRADYB2

Description: Kinins are small peptides produced rapidly following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) seem to initiate a similar cascade of events leading to neural tissue damage, as well as long lasting disturbances affecting blood-brain barrier function.1Kinins, such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK, exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). BKRB2 is activated by BK and Lys-BK while desArg9-BK and Lys-desArg9-BK activate BKRB1.2 Activation of BKRB2 liberates mediators of vascular tone, fibrinolysis, and pain. BKRB2, which mediates most of the physiological effects of kinins, as well as BKRB1, represent potential therapeutic targets for treatment of inflammatory disorders and cardiovascular diseases.Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxy terminus.BKRB2 is constitutively and widely expressed throughout the CNS and peripheral nervous system and on various cell types including endothelial cells, nerve fibers, leukocytes, and mast cells.3-5

ID gène: 624

NCBI Accession: NM_000623

UniProt: P30411

Pathways: ACE Inhibitor Pathway, Negative Regulation of intrinsic apoptotic Signaling